Product
CLL1 and CD38 dual-target CAR-T
1 clinical trial
1 indication
Indication
Acute Myeloid LeukemiaClinical trial
Clinical Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T Injection in the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-08-01